Overexpression of PD-L1 by tumor cells has been shown to inhibit CAR-T cell function, while combining CAR-T cell therapy with antibodies that block the PD1/PD-L1 interaction has proved to increase the antitumor effects of each therapy alone (71, 86, 87). This evidence concerns the gene PDCD1 and neoplasm.